Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $20.29 Consensus Target Price from Analysts

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has earned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $20.2857.

A number of equities research analysts recently commented on the stock. Rodman & Renshaw assumed coverage on shares of Enanta Pharmaceuticals in a report on Thursday, March 26th. They set a “buy” rating and a $20.00 price objective on the stock. Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Monday, April 20th.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENTA. AQR Capital Management LLC grew its position in shares of Enanta Pharmaceuticals by 674.7% in the 1st quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock valued at $1,971,000 after acquiring an additional 311,010 shares during the period. Millennium Management LLC grew its position in shares of Enanta Pharmaceuticals by 50.2% in the 1st quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock valued at $7,435,000 after acquiring an additional 449,945 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Enanta Pharmaceuticals by 5.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company’s stock valued at $720,000 after acquiring an additional 6,549 shares during the period. Invesco Ltd. grew its position in shares of Enanta Pharmaceuticals by 4.3% in the 2nd quarter. Invesco Ltd. now owns 62,884 shares of the biotechnology company’s stock valued at $475,000 after acquiring an additional 2,607 shares during the period. Finally, Marshall Wace LLP grew its position in shares of Enanta Pharmaceuticals by 0.8% in the 2nd quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock valued at $6,482,000 after acquiring an additional 6,522 shares during the period. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ:ENTA opened at $13.16 on Friday. Enanta Pharmaceuticals has a 12 month low of $5.87 and a 12 month high of $17.15. The company’s fifty day simple moving average is $13.61 and its 200 day simple moving average is $13.75. The firm has a market cap of $382.69 million, a price-to-earnings ratio of -5.08 and a beta of 1.01.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.01. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%. The business had revenue of $17.16 million for the quarter, compared to analyst estimates of $17.03 million. Research analysts expect that Enanta Pharmaceuticals will post -2.01 earnings per share for the current fiscal year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.